Oasmia Pharmaceutical AB
Interim report for the period May 2013 – January 2014
DGAP-News: Oasmia Pharmaceutical AB / 06.03.2014 / 08:58 --------------------------------------------------------------------- Continued development of the pre-clinical and clinical research program Uppsala, Sweden, 2014-03-06 08:58 CET (GLOBE NEWSWIRE) -- THIRD QUARTER November 1, 2013 - January 31, 2014 -- Consolidated Net sales amounted to EUR 2 thousand (0) [1] -- Operating income amounted to EUR - 3,221 thousand (-1,628) -- Net income after tax amounted to EUR - 3,440 thousand (-1,757) -- Earnings per share amounted to EUR - 0.04 (-0.02) -- Comprehensive income amounted to EUR - 3,440 thousand (-1,757) -- FDA approved Oasmia's production facility in Uppsala -- Increased financing by extension of the MSEK 105 loan from Nexttobe AB and a new MSEK 40 bank loan. THE PERIOD May 1, 2013 - January 31, 2014 -- Consolidated Net sales amounted to EUR 5 thousand (0) -- Operating income amounted to EUR -7,105 thousand (-5,162) -- Net income after tax amounted to EUR -7,610 thousand (-5,587) -- Earnings per share amounted to EUR -0.09 (-0.09) -- Comprehensive income amounted to EUR -7,610 thousand (-5,587) -- Oasmia initiated a clinical program for Paclical for treatment of breast cancer -- Oasmia initiated pre-clinical studies with OAS-19, the first pharmaceutical project with a combination of two active cytostatics in one infusion EVENTS AFTER CLOSING DAY -- Oasmia is granted conditional FDA approval for Paccal Vet [1]The numbers in brackets concern results from the corresponding period of the previous year News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 06.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Oasmia Pharmaceutical AB Sweden ISIN: SE0000722365 End of News DGAP News-Service --------------------------------------------------------------------- 256085 06.03.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden